ImmunoGen shares tank on ovarian cancer trial failure

ImmunoGen shares tank on ovarian cancer trial failure

Although an improvement in progression-free survival was shown in patients with high expression of the drug’s target, it did not reach statistical significance. The company’s shares lost half their value Friday.

Source: https://ift.tt/2IPiK56